Study on the practical application of chemo-radiotherapy for malignant brain tumor

裸鼠背部皮下接种人胶质瘤细胞GL9 10天后，测定CDDP对裸鼠的生长抑制作用，共给予CDDP 20 mg/kg，其中一组(高剂量CDDP组)10 mg/kg，隔10天一次，另一组(低剂量CDDP组)，2 mg/kg，每日一次。各组肿瘤体积测量显示，在肿瘤生长抑制效率方面，两组之间没有显著差异。接种21天后，测定每只小鼠的脾自然杀伤(NK)细胞活性。结果显示，低剂量顺铂组和高剂量顺铂组均明显低于对照组。7天后，将含有1 mM反义、正义或杂乱型硫代寡核苷酸的微渗泵与100ul无菌生理盐水连接成角度的插管，插入已建立的C6脑胶质瘤细胞瘤内。通过比较治疗10d后的肿瘤体积来判断反义硫代磷酸脱氧核苷酸对MAP-1AmRNA的影响。反义寡核苷酸治疗组肿瘤体积明显小于正义寡核苷酸组和错配寡核苷酸治疗组，提示小剂量顺铂联合MAP-1AmRNA反义治疗是治疗恶性脑肿瘤的有效方法。

Ten days after subcutaneous inoculation of human glioma cells, GL9, in the rear flank of nude mice, they were assesed for growth suppression by CDDP.Totally, 20mg/Kg of CDDP was administeredto each mouse ; in one group (high dose CDDP group), 10mg/Kg of CDDP on every tenth day, and in the other (low dose CDDP group), 2mg/Kg on every day. Measurement of the tumor volume in each group revealed no significant difference between the tow groups in terms of the efficiency of tumor growth suppresion. Twenty-one days after inoculation, we measure the splenic natural killer (NK) cell activity in eachi mouse. The results showed that the low-dose cisplatin group, and significantly decreased in the high-dase cisplatin group, as compared to the control group.C6 glioma cells with a concentration of 10^6 are implanted stereotactically within rat brain tissue. After 7 days, an angled cannula connected to a miniosmotic pump contained 1 mM antisense, sennse, or scramble phosphorothiorate oligodeoxynucleotide in 100 ul sterile saline is inserted into the established tumor of C6 glioma cells in each rat brain tissue. The effectiveness of antisense phosphorothionate oligodeoxynucleotide for MAP-1A mRNA was determined by comparing the tumor volume 10days after treatment. Tumor volume revealed to be significantly smaller in the antisense oligonucleotide group, as compared to the sense and scramble oligonuleotide group.The results of our studies suggest that the separate administration of low- dose CDDP and the antisense therapy for MAP-1A mRNA are useful treatment strategies for malignant brain tumors.